Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Inventory (2016 - 2025)

Ani Pharmaceuticals' Inventory history spans 14 years, with the latest figure at $143.1 million for Q4 2025.

  • For Q4 2025, Inventory rose 4.59% year-over-year to $143.1 million; the TTM value through Dec 2025 reached $143.1 million, up 4.59%, while the annual FY2025 figure was $143.1 million, 4.59% up from the prior year.
  • Inventory for Q4 2025 was $143.1 million at Ani Pharmaceuticals, down from $146.5 million in the prior quarter.
  • Across five years, Inventory topped out at $148.0 million in Q3 2024 and bottomed at $61.7 million in Q3 2021.
  • The 5-year median for Inventory is $106.0 million (2022), against an average of $109.1 million.
  • The largest annual shift saw Inventory soared 55.46% in 2022 before it decreased 1.06% in 2025.
  • A 5-year view of Inventory shows it stood at $81.7 million in 2021, then increased by 28.96% to $105.4 million in 2022, then increased by 5.54% to $111.2 million in 2023, then rose by 23.01% to $136.8 million in 2024, then grew by 4.59% to $143.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Inventory are $143.1 million (Q4 2025), $146.5 million (Q3 2025), and $138.3 million (Q2 2025).